An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease

Figures & data

Table 1 Characteristics of Patients with CD Receiving Ustekinumab

Characteristic		n (%)
Sex
	Male	124 (41.2)
	Female	177 (58.8)
Age category
	66+	36 (12.0)
	56–65	52 (17.3)
	41–55	82 (27.2)
	26–40	97 (32.2)
	19–25	33 (11.0)
	0–18	≤3
State*			% of Australian population in each state^#
	NSW	118 (39.2)	31.9
	VIC	79 (26.3)	26.0
	QLD	48 (16.0)	20.1
	SA	23 (7.6)	6.9
	WA	20 (6.6)	10.3
	TAS	5 (1.7)	2.1
	ACT	7 (2.3)	1.7
	NT	≤3^†	1.0
Prior use of biologic therapy
	Biologic-naive	91 (30.2)
	Biologic experienced	210 (69.8)

Notes: *The numbers in each state are not mutually exclusive as patients may have had ustekinumab dispensed in more than one state; ^#Calculated using Australian Bureau of Statistics data for 30 September 2019; ^†Exact numbers not reported by PBS for categories with three or fewer patients.

Table 2 12-Month Persistence of Ustekinumab by Prior Use of Biologic Therapy, Sex, Age and Combination or Monotherapy

	12-Month Persistence
		n	%	95% CI	p-value
Prior use of biologic therapy	Overall	157	82.6	78.1–87.5
	Biologic-naïve	44	88.0	80.8–95.9
	Biologic experienced	113	80.6	75.0–86.6	0.059
Sex	Male	71	89.8	84.2–95.8
	Female	86	77.3	70.7–84.5	<0.001
Age, years	15–34	55	82.8	75.2–91.2
	35–44	27	76.8	64.9–90.9	>0.5
	45–54	30	90.6	82.0–100	>0.5
	55–65	25	80.1	69.7–92.2	>0.5
	66+	20	82.7	71.1–96.4	>0.5
Combination therapy		60	84.9	77.8–92.6
Monotherapy		55	81.3	75.5–87.6	>0.05

Abbreviation: CI, confidence interval.

Figure 1 Kaplan–Meier estimate of overall persistence to ustekinumab.

Figure 2 Kaplan–Meier estimate of persistence to ustekinumab by prior use of biologic therapy.

Figure 3 Cox proportional hazards model including age, gender and prior use of biologic therapy.

Figure 4 Percentage of patients receiving ustekinumab as a monotherapy or in combination by prior use of biologic therapy.